Evidence map›Paper›PMID 41893792›Full record

ArticleVaccines2026

Transient Expression and Immunogenicity Assessment of the

Kotchaporn Jirananon, Kanokporn Thiganta, Kaewta Rattanapisit, Balamurugan Shanmugaraj, Waranyoo Phoolcharoen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kotchaporn JirananonBaiya Phytopharm Co., Ltd., Bangkok 10330, Thailand.
Kanokporn ThigantaBaiya Phytopharm Co., Ltd., Bangkok 10330, Thailand.
Kaewta RattanapisitBaiya Phytopharm Co., Ltd., Bangkok 10330, Thailand.
Balamurugan ShanmugarajCentre for Natural Products and Functional Foods, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India.
Waranyoo PhoolcharoenCenter of Excellence in Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0001-5958-7406

Funding

Chulalongkorn University Second Century Fund (C2F), Chulalongkorn University, Thailand Science and Research Innovation Fund Chulalongkorn University.
6 · The paper itself

Abstract

backgroundHouse dust mites (HDM) are one of the significant indoor allergen sources which cause IgE-mediated responses in most of the allergic individuals. HDMs are found in human habitats worldwide and Der p 2 is one of the major clinically relevant HDM allergens involved in triggering allergic diseases. The recombinant production of Der p 2 in plant systems provides a cost-effective and viable platform for developing diagnostic kits and allergen-specific immunotherapy.

methodsThe

resultsRecombinant Der p 2 was successfully expressed and purified from

conclusionsThe results demonstrate that the transient expression of Der p 2 in plants is a feasible and effective strategy for producing immunologically active recombinant allergen proteins for diagnostic and potential clinical applications.

Indexed as

Dermatophagoides pteronyssinushouse dust mite allergyNicotiana benthamianarecombinant proteintransient expressionvaccine

Identifiers

PMID41893792
PMCPMC13030849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.